Current Report Filing (8-k)
May 31 2016 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2016
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35006
|
|
93-0979187
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
11500 S. Eastern Ave., Ste. 240, Henderson, NV
|
|
89052
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (702) 835-6300
Not Applicable
(Former
name or former address if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On May 27, 2016, a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (Spectrum), Allos Therapeutics Inc. (the
Company), and Dr. Reddys Laboratories, Ltd. and Dr. Reddys Laboratories, Inc. (collectively, Dr. Reddys), entered into a settlement agreement to resolve their patent litigation relating to Folotyn
®
(pralatrexate injection). As a result of the settlement, Dr. Reddys will be permitted to market a generic version of Folotyn in the United States on December 1, 2022 or earlier
under certain circumstances. Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice. The parties will request that the court enter an order, in which it
will dismiss the Companys litigation against Dr. Reddys. As previously reported, the Company has also settled the litigation against Teva Pharmaceuticals USA, Inc. The Companys litigation against other generic filers
continues. This litigation is described in further detail in Part II, Item 1 of Spectrums Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the U.S. Securities and Exchange Commission on May 6,
2016.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Spectrum Pharmaceuticals, Inc.
|
|
|
|
|
Date: May 31, 2016
|
|
|
|
By:
|
|
/s/ Kurt A. Gustafson
|
|
|
|
|
|
|
Kurt A. Gustafson
|
|
|
|
|
|
|
Executive Vice President and Chief
|
|
|
|
|
|
|
Financial Officer
|
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024